Caesar Rivise reviews

Caesar Rivise has and still is showing signs of instability. In April 2019, Caesar Rivise's management announced to its staff that it was having troubles with profitability and it had to change its compensation structure. Since then, the firm has bled talent, losing half of its attorneys and its paralegals. The firm now lists a total of 11 attorneys, according to its website. By comparison, the firm had 20 lawyers at the beginning of 2019 and a high of 27 in 2007. Since 2012, Caesar Rivise has struggled amidst issues of succession (look at which attorneys are remaining) and business development. More recently, Caesar Rivise received another uppercut when a March 11, 2020 status report was published in Bayer Intellectual Property GMBH et al v. Taro Pharmaceutical Industries Ltd. et al, 1:17-cv-00462 (D. Del.) (ECF No. 213), stating that one of its former clients "stopped responding to [the firm]." At this point, the firm is a shell of its once prestigious self. Given the instability and staleness of the firm, prospective employees would be wise to look elsewhere for a more secure, successful firm.